Making Medicine

How does an MIT senior year capstone project evolve into an early-stage biotech that creates wearable solutions for Parkinson’s tremors? Listen to Daniel Carballo speak about the story of Encora Therapeutics in our MIT takeover episode, hosted by guest Lindsay Androski Founder, President, and CEO at Roivant Social Ventures and President, Board Member at Incubate Coalition.  In this episode, we dis...

As we follow innovation along the R&D value chain, we come across some compelling contributions to the healthcare ecosystem. Venture capital investors. Causal inference. Real world evidence. In this episode, we interview three guests about a collaboration story that represents the best of a healthy healthcare ecosystem: Janis Naeve, Managing Director, Amgen Ventures at Amgen and Incubate Board Tre...

The price control policies that are being discussed in Congress have the potential to harm innovation in the life science industry. But how, exactly? In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates , about what would change in biopharma if price controls were implemented. In this episode, we discuss: The close relationship between economy and drug develop...

What goes into a bottle of new medicine is more than the proverbial 15 years and $2 billion. It takes great science, certainly, but it also takes 15 years of relationships. No one can make medicine alone, not even Big Pharma. Collaboration, innovation, and industry relationships are key to bringing life-saving medicine to market. In this episode, I interview Imran Nasrullah, Vice President & Head,...

High cost out-of-pocket drugs and obstacles to reduce those prices for patients plague the health industry. With patients in mind, organizations are looking to invest and bring drugs directly to market. Gaurav Gupta and Hugo Beekman, Co-Founders of Ascendant BioCapital, join the show to discuss their organization and how they’re focusing on drugs that truly make a difference for patients. What we...

As it turns out, many perceptions about the pharmaceutical industry are based without all of the facts. That’s why we’re sitting down to understand the data with Ravi Mehrotra, Thought Leader and former Senior Managing Director of Biotechnology Equity Research at Evercore ISI. What we talked about: - Defining WBPI while taking a closer look at the industry - The reality that winners pay for all th...

Intellectual property (IP) rights have been the driving force behind innovation and entrepreneurship. However, IP has more recently been seen in a negative light. Through the COVID-19 Pandemic, vaccine IP rights have come into question: should IP rights be waived when concerning an essential technology? Andrei Iancu, Former Under Secretary of Commerce for Intellectual Property and Director of the...

The fight against Antimicrobial Resistance (AMR) is challenging due to financial, ethical, and legislative issues. Combating infectious disease can prove to be a risky financial investment but much less in comparison to the global impact if solutions are not researched. Alfonso Chang is the Managing Director of Relativity Healthcare Partners; he shares insight into the challenges and how to overco...

In 1980, the Bayh-Dole Act was enacted by U.S. Congress, which changed how ownership of an invention is pursued. Almost 40 years later, how has this act fared? On Episode 1 of Making Medicine, John Stanford, Executive Director of Incubate Coalition, introduces Joseph Allen and Associates to cover: - How Bayh-Dole came to be, starting with Purdue University - The original intent of ‘march-in’ right...

From chance meetings to risky investments, Making Medicine explores the origin stories of life changing medication and how patients, corporations and investment communities benefit from understanding it. On today’s episode, Kelsey Kohrs, Producer at Sweet Fish Media and John Stanford, Executive Director of Incubate Coalition introduce Making Medicine, a podcast dedicated to sharing life science st...